RenovoRx Announces Sixth U.S. Patent
RenovoRx, an innovator in targeted cancer therapy, today announced the United States Patent and Trademark Office has allowed U.S. Patent Application number 15,807,011. This new patent will broadly cover RenovoRx’s unique therapeutic method called Trans-Arterial Micro-Perfusion (TAMPTM) which is designed for targeted delivery of chemotherapeutic agents to treat tumors with a proprietary catheter in conjunction with radiation. The TAMP method patent will expand RenovoRx’s patent portfolio and will be the Company’s sixth U.S. patent and the second patent issued in the past six months.
RenovoRx Announces Sixth U.S. Patent
RenovoRx today announced the United States Patent and Trademark Office has allowed U.S. Patent Application number 15,807,011. This new patent will broadly cover RenovoRx’s unique therapeutic method called Trans-Arterial Micro-Perfusion (TAMPTM) which is designed for targeted delivery of chemotherapeutic agents to treat tumors with a proprietary catheter in conjunction with radiation. The TAMP method patent will expand RenovoRx’s patent portfolio and will be the Company’s sixth U.S. patent and the second patent issued in the past six months.